Ascendis Pharma Closes $124 Million Initial Public Offering
Palo Alto – February 13, 2015 – Cooley advised the underwriters on Ascendis Pharma A/S's $124.2 million initial public offering. Ascendis Pharma is a clinical-stage biopharmaceutical company applying its TransCon technology to develop a pipeline of therapies to address significant unmet medical needs. The company now trades on The Nasdaq Global Market under the symbol "ASND."
Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Partners LLC acted as the joint book-running managers and Wells Fargo Securities, LLC acted as co-manager for the offering.
The Cooley corporate securities team advising the underwriters was comprised of partners Div Gupta, Drew Williamson and Charlie Kim, as well as associates Jonie Ing Kondracki, Carolyn Mo, Kristin VanderPas and Jenny Baer Tuohy.
Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); partner Bill Christiansen (intellectual property); partner Lila Hope and associate Jennifer Raab (life sciences partnering); special counsel Laura McDaniels (compensation and benefits); and partner Susan Cooper Philpot (tax).
About Cooley LLP
Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.